Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Solasta Bio Limited has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 2 actions are assigned to 2 distinct examiners but are both located within 1 distinct art unit. KOMATSU, LI N is the busiest examiner, holding 1 pending office action. The concentration of both pending office actions in 1 distinct art unit suggests a specific technical focus within biotechnology.
Although there are 2 distinct examiners, the fact that they are in the same art unit means they likely follow similar internal guidelines. However, since the busiest examiner, KOMATSU, LI N, only has 1 action, each examiner must be approached individually. The prosecution strategy should prioritize the specific standards and practices of the 1 art unit involved. Practitioners must manage 2 separate relationships and sets of examiner preferences within the 1 distinct art unit.
The outcome of the 2 pending office actions will impact the company intellectual property standing in the biotechnology field. Strategy should be focused on the individual requirements of the 1 art unit within the Biotechnology & Pharmaceuticals area. The 2 pending office actions represent the current prosecution risk for the company. Each application requires a unique approach tailored to the specific examiner and the technical standards of the 1 art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| §103 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KOMATSU, LI N | 1 | 59.8% | +71.0% |
| FISCHER, JOSEPH | 1 | 43.4% | +45.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19090002 | INSECT NEUROPEPTIDES 3 | FISCHER, JOSEPH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19089551 | INSECT NEUROPEPTIDES 1 | KOMATSU, LI N | — |
| 19090002 | INSECT NEUROPEPTIDES 3 | FISCHER, JOSEPH | — |
| Art Unit | Apps |
|---|---|
| 1658 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19089551 | INSECT NEUROPEPTIDES 1 | KOMATSU, LI N | 1658 | §103 | Final Rejection | — | Pending | Mar 25, 2025 |
| 19090002 | INSECT NEUROPEPTIDES 3 | FISCHER, JOSEPH | 1658 | §101§103§112 | Final Rejection | — | Pending | Mar 25, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSolasta Bio Limited has 2 pending office actions as of October 2026, spread across 1 art units and 2 examiners.
Li N Komatsu has the most, with 1 of Solasta Bio Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
